December 30, 2022 7:52am

To save our market and sector sanity

Pre-open Indication: NONE

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

Happy soon-to-be New Year 2023; the 8:00 a.m. edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.40% or (-133 points), S&P futures are DOWN -0.57% or (-22 point) and NASDAQ futures are DOWN -0.86% or (-95 points) early in the pre-open – so far,

Stock futures slip lower awaiting its final trading day of 2022,

European markets were down as the U.K.’s FTSE 100 slid 0.3%, the CAC 40 was down 0.6% and the German DAX dived lower by 0.5%. The Stoxx 600 was down 0.4%,

Asia-Pacific markets rose in final trading session of 2022.



We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Investors head into the final trading day of 2022.

  • Thursday, the Dow closed UP +345.09 points (+1.05%), the S&P closed UP +66.06 points (+1.75%) while the Nasdaq closed UP +264.80 points (+2.59%)

For the week so far, the Dow advanced +0.05%, the S&P +0.12%, while the Nasdaq experience a -0.19% loss.

Today marks the final day of trading of a painful year for stocks, volatile market, sticky inflation, and aggressive rate hikes from the Fed which have battered cell and gene therapy equities weighing on investor sentiment.

Economic Data Docket: Chicago PMI data for December


Thursday’s (9/29) … RegMed Investors’ (RMi) closing bell: “uncle algorithms to the upside. The share pricing scars still exist as volume remains mostly low with only one (1) decliner – a usual suspect – Biostage (OTCQB: BSTG). Is it Beijing, China’s “plant’ in U.S.’ biotech universe?? Question should need an answer?” …


Ebb and flow:

Q4 – December – 1 holiday, 13 negative and 7 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

  • It's done ... 2022


The BOTTOM LINE: I try to keep it simple and short!

If you've had a bad year, you're not going to make it up in the final two trading days of 2022 with the market struggling. Learn from your mistakes and prepare for the next sustained market rally in 2023. <IBD>

There's nothing wrong with taking no new positions, or even being entirely in cash.

Be prepared … just today’s trading day remains in 2022.

With so much uncertainty about the new year, a cautious outlook seems prudent.

Short and near-term trends and investing norms are shifting. Investors must watch carefully for sector changes and try to make smart stock picks.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.